The takeover comes as sales of BMS's blood cancer drug Revlimid, its 3rd-largest revenue driver, withered in the face of generic rivals and its blockbuster Opdivo is also scheduled to face competition from generics later this decade.
The limits stem from an opioid settlement with AmerisourceBergen, Cardinal Health and McKesson that flag and sometimes block controlled substances – and patients with anxiety and sleep disorder are caught in the crosshairs.